Published in J Nucl Med on June 01, 2005
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest (2006) 2.08
Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging (2012) 1.56
Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40
Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. Neuroimage (2010) 1.14
Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol (2009) 0.95
Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging (2008) 0.94
Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med (2011) 0.94
Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol (2007) 0.90
In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol (2009) 0.89
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2). ACS Chem Biol (2013) 0.84
Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET. EJNMMI Res (2011) 0.82
PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons. Nucl Med Biol (2012) 0.81
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 0.80
Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. Eur Radiol (2014) 0.79
Derivatization of (±) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2. Bioorg Med Chem Lett (2014) 0.79
Biomarkers in Alzheimer's disease. Front Neurol (2011) 0.79
Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. Arch Neurol (2010) 0.79
Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2016) 0.78
Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity. J Clin Endocrinol Metab (2011) 0.78
Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value? PLoS One (2015) 0.77
Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis. J Org Chem (2015) 0.77
Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications. Ann Neurol (2015) 0.75
A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2. PLoS One (2016) 0.75
NIH workshop on clinical translation of molecular imaging probes and technology--meeting report. Mol Imaging Biol (2014) 0.75
Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging (2008) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology (2013) 3.56
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Validation of a polysomnographic score for REM sleep behavior disorder. Sleep (2005) 3.02
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
The role of engagement in a tailored web-based smoking cessation program: randomized controlled trial. J Med Internet Res (2008) 2.64
Hippocampal inactivation disrupts the acquisition and contextual encoding of fear extinction. J Neurosci (2005) 2.55
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain (2010) 2.37
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab (2006) 2.16
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord (2004) 2.13
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab (2006) 2.01
Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology (2013) 2.00
Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet (2010) 1.99
Initial agonist treatment of Parkinson disease: a critique. Neurology (2003) 1.82
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol (2007) 1.76
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord (2012) 1.69
Early menopausal hormone use influences brain regions used for visual working memory. Menopause (2010) 1.67
Evaluation of four proposed bleeding criteria for the onset of late menopausal transition. J Clin Endocrinol Metab (2006) 1.67
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology (2014) 1.59
Rodent genetic models of Huntington disease. Neurobiol Dis (2008) 1.58
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55
C9ORF72 expansion in a family with bipolar disorder. Bipolar Disord (2013) 1.54
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol (2003) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol (2004) 1.51
Screening experiments and the use of fractional factorial designs in behavioral intervention research. Am J Public Health (2008) 1.50
Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab (2013) 1.49
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) (2006) 1.48
A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plast Reconstr Surg (2011) 1.48
PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med (2006) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology (2002) 1.45
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann Neurol (2006) 1.41
Procedure guideline for brain death scintigraphy. J Nucl Med (2003) 1.41
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer (2009) 1.39
In vivo, Pikfyve generates PI(3,5)P2, which serves as both a signaling lipid and the major precursor for PI5P. Proc Natl Acad Sci U S A (2012) 1.39
EMG variance during polysomnography as an assessment for REM sleep behavior disorder. Sleep (2007) 1.38
The cholinergic system and Parkinson disease. Behav Brain Res (2010) 1.38
Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. J Neurosci (2007) 1.38
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol (2008) 1.37
NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw (2009) 1.35
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2004) 1.33
Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab (2012) 1.32
Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol (2005) 1.31
White matter lesions in Parkinson disease. Nat Rev Neurol (2011) 1.30
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther (2007) 1.29
Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry (2012) 1.29
Molecular and pathological effects of a modifier gene on deficiency of the sodium channel Scn8a (Na(v)1.6). Hum Mol Genet (2002) 1.29
Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol (2009) 1.29
SNM practice guideline for brain death scintigraphy 2.0. J Nucl Med Technol (2012) 1.28
The ReSTAGE Collaboration: defining optimal bleeding criteria for onset of early menopausal transition. Fertil Steril (2007) 1.28
Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis (2012) 1.27
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
Protein synthesis in the amygdala, but not the auditory thalamus, is required for consolidation of Pavlovian fear conditioning in rats. Eur J Neurosci (2003) 1.21
Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol (2006) 1.20
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol (2008) 1.18
Extensions of the penalized spline of propensity prediction method of imputation. Biometrics (2008) 1.17
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2008) 1.14
Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol (2012) 1.14